Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis
| Status: | Completed |
|---|---|
| Conditions: | Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/7/2019 |
| Start Date: | February 1, 2017 |
| End Date: | January 10, 2018 |
Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis (REACT-CF)
This is a pilot study investigating the effectiveness and clinical efficacy of airway
clearance therapy (ACT) in cystic fibrosis (CF). Enrolled subjects will undergo measurements
of mucociliary clearance (MCC) and exhaled biomarkers at baseline and after 3 different forms
of ACT: high frequency chest wall oscillatory vest, oscillatory positive expiratory pressure
device, and whole-body vibration.
clearance therapy (ACT) in cystic fibrosis (CF). Enrolled subjects will undergo measurements
of mucociliary clearance (MCC) and exhaled biomarkers at baseline and after 3 different forms
of ACT: high frequency chest wall oscillatory vest, oscillatory positive expiratory pressure
device, and whole-body vibration.
Inclusion Criteria:
- Adults with confirmed diagnosis of cystic fibrosis aged 18 years and older.
Exclusion Criteria:
- Pregnant or lactating women,
- Individuals with severe lung disease (FEV1 <30%), or with exacerbations of lung
disease requiring antibiotics or medication change within four weeks prior to
enrolment.
- Individuals unable to use vest-based HFCWO, OPEP device, or who require oxygen
supplementation at rest.
- Individuals with significant balance or gait impairment preventing them from
tolerating being positioned on a vibrating platform.
We found this trial at
1
site
Click here to add this to my saved trials
